Soiken Holdings (TSE:2385) EBIT: 円81 Mil (TTM As of Dec. 2025)


TSE:2385 Soiken Holdings Inc TSE:2385
56 GF Score
Price 円209.00
GF Value 円114.55
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Soiken Holdings EBIT?

Soiken Holdings TSE:2385 +1.46% 56 EBIT is 円81 Mil as of Dec. 2025. GuruFocus rates TSE:2385 with a GF Score™ of 56/100 and a GF Value™ of 円114.55 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Soiken Holdings's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was 円0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was 円81 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Soiken Holdings's annualized ROC % for the quarter that ended in Dec. 2025 was 0.00%. Soiken Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Soiken Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -45.67%.


Soiken Holdings  (TSE:2385) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Soiken Holdings's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=0 * ( 1 - 0% )/( (1340.621 + 1194.791)/ 2 )
=0/1267.706
=0.00 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6812.899 - 213.927 - ( 5258.351 - max(0, 756.194 - 6597.302+5258.351))
=1340.621

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6671.51 - 152.629 - ( 5324.09 - max(0, 608.468 - 6441.406+5324.09))
=1194.791

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Soiken Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (9.601 + max(582.757, 0)) + (41.463 + max(508.848, 0)) )/ 2 )
=0/( ( 592.358 + 550.311 )/ 2 )
=0/571.3345
=0.00 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(223.883 + 926.515 + 188.553) - (213.927 + 0 + 542.267)
=582.757

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(284.04 + 740.565 + 92.711) - (152.629 + 0 + 455.839)
=508.848

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Soiken Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=80.747/-176.814
=-45.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Soiken Holdings EBIT Related Terms


Soiken Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Soiken Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Soiken Holdings EBIT Chart

Soiken Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 916.79 1,208.77 725.72 -610.01 -137.54

Soiken Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 79.65 -14.15 0.00 94.90

TSE:2385 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Soiken Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Soiken Holdings EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Soiken Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Soiken Holdings's EV-to-EBIT falls into.


TSE:2385
56GF Score
Soiken Holdings Inc TSE:2385
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Soiken Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円81 Mil mean?
Soiken Holdings (TSE:2385) has a EBIT of 円81 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Soiken Holdings.
Is Soiken Holdings' EBIT too high?
Soiken Holdings' current EBIT is 円81 Mil. Overall, Soiken Holdings has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soiken Holdings' EBIT compare to VRTX and REGN?
Soiken Holdings' EBIT of 円81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Soiken Holdings. Soiken Holdings's current EBIT is 円81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soiken Holdings stock overvalued right now?
Based on GuruFocus' analysis, Soiken Holdings (TSE:2385) is currently considered Significantly Overvalued. The stock's GF Value™ is 円114.55, compared to a current price of 円209.00 — trading 82.5% above its estimated fair value. The current EBIT is 円81 Mil. Soiken Holdings' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Soiken Holdings (TSE:2385), the current EBIT is 円81 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Soiken Holdings (TSE:2385) Overvalued in 2026?

Based on GuruFocus' analysis, Soiken Holdings stock appears to be overvalued. The current stock price of 円209.00 is trading 82.5% above its estimated GF Value™ of 円114.55. GuruFocus considers Soiken Holdings to be Significantly Overvalued.

Key valuation signals for TSE:2385:

  • EBIT: 円81 Mil
  • GF Value™: 円114.55 vs. price of 円209.00 (82.5% above fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the TSE:2385 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Soiken Holdings Business Description

Address 1-4-2 Shinsenri-Higashimachi, 13th Floor, Senri Life Science Center, Toyonaka, Osaka, JPN, 560-0082
Soiken Holdings Inc operates as a biotechnology company in Japan. It provides clinical testing for pharmaceutical and food manufacturers that develop drugs and health food products based on biomarkers. It is involved in the marketing research and post-marketing surveillance of health supplements.
56GF Score

Get the complete analysis for TSE:2385

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円209.00
Price
円114.55
GF Value